You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 7, 2024

COVIS Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for COVIS
International Patents:144
US Patents:5
Tradenames:12
Ingredients:9
NDAs:11

Drugs and US Patents for COVIS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Covis SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-003 Feb 2, 1995 DISCN Yes No ⤷  Sign Up ⤷  Sign Up
Covis ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-003 Jun 26, 2002 RX Yes No ⤷  Sign Up ⤷  Sign Up
Covis LANOXIN PEDIATRIC digoxin INJECTABLE;INJECTION 009330-004 Approved Prior to Jan 1, 1982 RX Yes Yes ⤷  Sign Up ⤷  Sign Up
Covis OMNARIS ciclesonide SPRAY, METERED;NASAL 022004-001 Oct 20, 2006 RX Yes Yes 8,371,292 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for COVIS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Covis ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-002 Jun 26, 2002 6,485,748 ⤷  Sign Up
Covis ALVESCO ciclesonide AEROSOL, METERED;INHALATION 021658-003 Jan 10, 2008 5,482,934 ⤷  Sign Up
Covis FERAHEME ferumoxytol SOLUTION;INTRAVENOUS 022180-001 Jun 30, 2009 8,591,864 ⤷  Sign Up
Covis SULAR nisoldipine TABLET, EXTENDED RELEASE;ORAL 020356-006 Jan 2, 2008 5,626,874 ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for COVIS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 30 mg/mL, 17 mL single-use vials ➤ Subscribe 2015-12-04
➤ Subscribe Extended-release Tablets 20 mg and 30 mg ➤ Subscribe 2007-11-07
➤ Subscribe Extended-release Tablets 40 mg ➤ Subscribe 2007-06-11
➤ Subscribe Nasal Spray 250 mcg ➤ Subscribe 2012-02-13
➤ Subscribe Extended-release Tablets 25.5 mg and 34 mg ➤ Subscribe 2008-11-28
➤ Subscribe Extended-release Tablets 8.5 mg and 17 mg ➤ Subscribe 2009-03-02

Supplementary Protection Certificates for COVIS Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1200431 132013902117495 Italy ⤷  Sign Up PRODUCT NAME: BROMURO DI ACLIDINIO(EKLIRA GENUAIR E BRETARIS GENUAIR); AUTHORISATION NUMBER(S) AND DATE(S): BRETARIS G.: EU/1/12/781/001-002-003; EKLIRA G.:EU/1/12/778/001-002-003, 20120720
1169062 300558 Netherlands ⤷  Sign Up PRODUCT NAME: FERUMOXYTOL IN IEDERE DOOR HET BASISOCTROOI BESCHERMDE VORM; REGISTRATION NO/DATE: EU/1/12/774/001-002 20120615
1200431 13C0001 France ⤷  Sign Up PRODUCT NAME: SEL D'ACLIDINIUM AVEC UN ANION PHARMACEUTIQUEMENT ACCEPTABLE D'UN ACIDE MONO OU POLYVALENT, EN PARTICULIER LE BROMURE D'ACLIDINIUM; REGISTRATION NO/DATE: EU/1/12/778/001-003 20120720
1411900 SPC/GB11/015 United Kingdom ⤷  Sign Up PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.